U. Moran

发表

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

I. Osman, A. Pavlick, A. Izsak, 2019, Genome Medicine.

The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic

I. Osman, U. Moran, C. Arguelles-Grande, 2020, Journal of Translational Medicine.

A Deep Learning Approach for Rapid Mutational Screening in Melanoma

N. Razavian, N. Coudray, T. Sakellaropoulos, 2019, bioRxiv.

Melanoma Prognosis - Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.

D. Polsky, I. Osman, A. Pavlick, 2020, Journal of the National Cancer Institute.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors

I. Osman, U. Moran, J. Zhong, 2020, Journal of translational medicine.

Impact of initial stage on metastatic melanoma survival

D. Polsky, I. Osman, A. Pavlick, 2019, Melanoma research.

The urgency of utilizing COVID-19 biospecimens for research in the heart of the global pandemic

I. Osman, U. Moran, C. Arguelles-Grande, 2020, Journal of Translational Medicine.

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

T. Kirchhoff, I. Osman, A. Pavlick, 2018, Journal of Translational Medicine.

Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)

T. Kirchhoff, D. Polsky, I. Osman, 2019, Scientific Reports.

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy

T. Kirchhoff, D. Polsky, I. Osman, 2018, Journal of the National Cancer Institute.

Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma

I. Osman, G. Jour, H. Zhong, 2020, Modern Pathology.

Functional analysis of RPS27 mutations and expression in melanoma

T. Kirchhoff, I. Dolgalev, I. Osman, 2020, Pigment cell & melanoma research.

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition

R. Sullivan, K. Flaherty, Dennie T. Frederick, 2019, Cancer Immunology, Immunotherapy.

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

I. Osman, A. Pavlick, A. Izsak, 2019, Genome Medicine.

Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma

R. Hayes, I. Osman, Jiyoung Ahn, 2021, Genome medicine.

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

S. W. Han, D. Polsky, P. Ott, 2017, Oncology.

Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma

I. Osman, A. Pavlick, U. Moran, 2020, Melanoma research.

Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy

I. Osman, A. Pavlick, U. Moran, 2020, Journal of surgical oncology.

A genome-wide association study of germline variation and melanoma prognosis

T. Kirchhoff, M. Snuderl, I. Osman, 2023, Frontiers in Oncology.

The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence

S. Lakhani, D. Adams, C. Parkinson, 2020, British journal of cancer.

Deep learning and pathomics analyses reveal cell nuclei as important features for mutation prediction of BRAF-mutated melanomas.

N. Razavian, N. Coudray, T. Sakellaropoulos, 2021, The Journal of investigative dermatology.

The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence

S. Lakhani, D. Adams, C. Parkinson, 2020, British Journal of Cancer.

Mutation burden as a potential prognostic marker of melanoma progression and survival.

Adriana Heguy, A. Heguy, T. Kirchhoff, 2017 .

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis

I. Osman, A. Pavlick, Hsin-Hui Huang, 2018, Journal of Immunotherapy for Cancer.

Hotspot KRAS mutations in brain metastases at the first metastatic recurrence of cutaneous melanoma

S. Lakhani, D. Adams, C. Parkinson, 2020, bioRxiv.

Association of Initial Viral Load in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients with Outcome and Symptoms

A. Heguy, A. Troxel, M. Snuderl, 2020, The American Journal of Pathology.

ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS

A. Heguy, A. Troxel, M. Snuderl, 2020, The American Journal of Pathology.

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

Michael F. Sharpnack, D. Schadendorf, R. Sullivan, 2018, Journal of Translational Medicine.

ASSOCIATION OF INITIAL VIRAL LOAD IN SARS-CoV-2 PATIENTS WITH OUTCOME AND SYMPTOMS.

A. Heguy, A. Troxel, M. Snuderl, 2020, The American journal of pathology.

Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM)

T. Kirchhoff, D. Polsky, I. Osman, 2019, Scientific Reports.

Using digital-image analysis of tumor-infiltrating lymphocytes to predict survival outcomes in primary melanoma.

I. Osman, G. Jour, K. Giles, 2020 .

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

S. W. Han, D. Polsky, P. Ott, 2017, Oncology.